SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-113766"
 

Search: onr:"swepub:oai:DiVA.org:oru-113766" > Use of beta-blocker...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Strell, CarinaDepartment of Immunology, Genetics, and Pathology, Uppsala University, Dag Hammarskjölds Väg 20, 751 85, Uppsala, Sweden; Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway (author)

Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence : a Swedish retrospective cohort study

  • Article/chapterEnglish2024

Publisher, publication year, extent ...

  • Springer-Verlag New York,2024
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-113766
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-113766URI
  • https://doi.org/10.1007/s10549-024-07358-yDOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-225016URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:158254620URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies:Uppsala UniversitySwedish Cancer SocietySwedish research CouncilTrond Mohn Foundation
  • BACKGROUND: Retrospective observational studies suggest a potential role of beta-blockers as a protective strategy against progression and metastasis in invasive breast cancer. In this context, we investigated the impact of beta-blocker exposure on risk for progression to invasive breast cancer after diagnosis of ductal cancer in situ (DCIS).METHODS: The retrospective study population included 2535 women diagnosed with pure DCIS between 2006 and2012 in three healthcare regions in SwedenExposure to beta-blocker was quantified using a time-varying percentage of days with medication available. The absolute risk was quantified using cumulative incidence functions and cox models were applied to quantify the association between beta-blocker exposure and time from DCIS diagnosis to invasive breast cancer, accounting for delayed effects, competing risks and pre-specified confounders.RESULTS: The median follow-up was 8.7 years. One third of the patients in our cohort were exposed to beta-blockers post DCIS diagnosis. During the study period, 48 patients experienced an invasive recurrence, giving a cumulative incidence of invasive breast cancer progression of 1.8% at five years. The cumulative exposure to beta-blocker was associated with a reduced risk in a dose-dependent manner, though the effect was not statistically significant.CONCLUSION: Our observational study is suggestive of a protective effect of beta-blockers against invasive breast cancer after primary DCIS diagnosis. These results provide rationales for experimental and clinical follow-up studies in carefully selected DCIS groups.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Smith, Daniel,1981-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden(Swepub:oru)dlsh (author)
  • Valachis, Antonis,1984-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Oncology, Faculty of Medicine and Health, Örebro University Hospital, Örebro University, Örebro, Sweden(Swepub:oru)asvs (author)
  • Woldeyesus, HellénDepartment of Oncology, Uppsala University Hospital, Uppsala, Sweden (author)
  • Wadsten, CharlottaUmeå universitet,Kirurgi,Department of Surgery, Sundsvall Hospital, Sundsvall, Sweden(Swepub:umu)chwa0052 (author)
  • Micke, PatrickDepartment of Immunology, Genetics, and Pathology, Uppsala University, Dag Hammarskjölds Väg 20, 751 85, Uppsala, Sweden (author)
  • Fredriksson, IrmaDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Breast, Endocrine Tumors and Sarcoma, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden (author)
  • Schiza, AglaiaDepartment of Immunology, Genetics, and Pathology, Uppsala University, Dag Hammarskjölds Väg 20, 751 85, Uppsala, Sweden; Department of Oncology, Uppsala University Hospital, Uppsala, Sweden (author)
  • Department of Immunology, Genetics, and Pathology, Uppsala University, Dag Hammarskjölds Väg 20, 751 85, Uppsala, Sweden; Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, NorwayInstitutionen för medicinska vetenskaper (creator_code:org_t)

Related titles

  • In:Breast Cancer Research and Treatment: Springer-Verlag New York207:2, s. 293-2990167-68061573-7217

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view